| 5.42 0.04 (0.74%) | 10-07 11:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 6.94 | 1-year : | 7.75 |
| Resists | First : | 5.94 | Second : | 6.63 |
| Pivot price | 5.48 |
|||
| Supports | First : | 4.82 | Second : | 4.01 |
| MAs | MA(5) : | 5.46 |
MA(20) : | 5.39 |
| MA(100) : | 5.66 |
MA(250) : | 7.14 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 36 |
D(3) : | 40.2 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 13.68 | Low : | 3.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALGS ] has closed above bottom band by 48.9%. Bollinger Bands are 73.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.42 - 5.45 | 5.45 - 5.47 |
| Low: | 5.22 - 5.26 | 5.26 - 5.29 |
| Close: | 5.32 - 5.39 | 5.39 - 5.43 |
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Mon, 05 Oct 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 - Investing News Network
Mon, 05 Oct 2026
Aligos Therapeutics Announces Five Abstracts Accepted for Presentation at The Liver Meeting® 2026 - The Manila Times
Mon, 05 Oct 2026
One Aligos hepatitis B abstract is marked “Poster of Distinction” at the 2026 liver meeting. - Stock Titan
Fri, 02 Oct 2026
Aligos Therapeutics Stock Price Forecast. Should You Buy ALGS? - StockInvest.us
Fri, 25 Sep 2026
ALGS News | ALIGOS THERAPEUTICS INC (NASDAQ:ALGS) - ChartMill
Wed, 16 Sep 2026
Aligos Therapeutics Amends Long-Term Headquarters Lease Agreement - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.7e+006 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 568 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -7.792e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -241.1 % |
| Operating Margin | -6.9 % |
| Return on Assets (ttm) | -49.2 % |
| Return on Equity (ttm) | -113.6 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | 334.12 |
| Sales Per Share | 1.35279e+007 |
| EBITDA (p.s.) | -2.44034e+007 |
| Qtrly Earnings Growth | -7.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -94 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.49 |
| Dividend | 0 |
| Forward Dividend | 697680 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|